ArticleCell reports. Medicine2025

Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies.

Juanita S Lopez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.